These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 17965424

  • 1. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
    Krueger K, Lino L, Dore R, Radominski S, Zhang Y, Kaur A, Simpson R, Curtis S.
    Ann Rheum Dis; 2008 Mar; 67(3):315-22. PubMed ID: 17965424
    [Abstract] [Full Text] [Related]

  • 2. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
    Baraf HS, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, Soffer B, Polis A, Bird S, Kaur A, Curtis SP, EDGE Study Group.
    J Rheumatol; 2007 Feb; 34(2):408-20. PubMed ID: 17304660
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).
    Combe B, Swergold G, McLay J, McCarthy T, Zerbini C, Emery P, Connors L, Kaur A, Curtis S, Laine L, Cannon CP.
    Rheumatology (Oxford); 2009 Apr; 48(4):425-32. PubMed ID: 19223284
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L, MEDAL Steering Committee.
    Lancet; 2006 Nov 18; 368(9549):1771-81. PubMed ID: 17113426
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
    Cannon CP, Curtis SP, Bolognese JA, Laine L, MEDAL Steering Committee.
    Am Heart J; 2006 Aug 18; 152(2):237-45. PubMed ID: 16875903
    [Abstract] [Full Text] [Related]

  • 8. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
    Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CP.
    Gastroenterology; 2008 Nov 18; 135(5):1517-25. PubMed ID: 18823986
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Perioperative blood loss and gastrointestinal tolerability of etoricoxib and diclofenac in total hip arthroplasty (ETO-DIC study): a single-center, prospective double-blinded randomized controlled trial.
    Winkler SH, Barta S, Kehl V, Schröter C, Wagner F, Grifka J, Springorum HR, Craiovan B.
    Curr Med Res Opin; 2016 Nov 18; 32(1):37-47. PubMed ID: 26414653
    [Abstract] [Full Text] [Related]

  • 12. [By what means does the rheumatic patient with gastrointestinal risks fare best?].
    Einecke D.
    MMW Fortschr Med; 2007 Mar 08; 149(10):18. PubMed ID: 17408040
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
    Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, Lines CR, Gertz BJ, Curtis S, Etoricoxib Rheumatoid Arthritis Study Group.
    J Rheumatol; 2002 Aug 08; 29(8):1623-30. PubMed ID: 12180720
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489].
    Curtis SP, Bockow B, Fisher C, Olaleye J, Compton A, Ko AT, Reicin AS.
    BMC Musculoskelet Disord; 2005 Dec 01; 6():58. PubMed ID: 16321158
    [Abstract] [Full Text] [Related]

  • 19. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis.
    Zacher J, Feldman D, Gerli R, Scott D, Hou SM, Uebelhart D, Rodger IW, Ozturk ZE, etoricoxib OA study group.
    Curr Med Res Opin; 2003 Dec 01; 19(8):725-36. PubMed ID: 14687444
    [Abstract] [Full Text] [Related]

  • 20. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
    Feng X, Tian M, Zhang W, Mei H.
    PLoS One; 2018 Dec 01; 13(1):e0190798. PubMed ID: 29320568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.